115 related articles for article (PubMed ID: 30694085)
1. RE: A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy, and Spain.
Lass A; Montgomery SM
J Med Econ; 2019 Apr; 22(4):379-380. PubMed ID: 30694085
[No Abstract] [Full Text] [Related]
2. A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain.
Gizzo S; Ferrando M; Lispi M; Ripellino C; Cataldo N; Bühler K
J Med Econ; 2018 Nov; 21(11):1096-1101. PubMed ID: 30113238
[TBL] [Abstract][Full Text] [Related]
3. Reply: RE: a cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy, and Spain.
Gizzo S; Ferrando M; Lispi M; Ripellino C; Cataldo N; Bühler K
J Med Econ; 2019 Apr; 22(4):381-382. PubMed ID: 30691336
[No Abstract] [Full Text] [Related]
4. Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis.
Chua SJ; Mol BW; Longobardi S; Orvieto R; Venetis CA; Lispi M; Storr A; D'Hooghe T
Reprod Biol Endocrinol; 2021 Apr; 19(1):51. PubMed ID: 33794909
[TBL] [Abstract][Full Text] [Related]
5. Economic Evaluation of Three Frequently Used Gonadotrophins in Assisted Reproduction Techniques in the Management of Infertility in the Netherlands.
Fragoulakis V; Pescott CP; Smeenk JM; van Santbrink EJ; Oosterhuis GJ; Broekmans FJ; Maniadakis N
Appl Health Econ Health Policy; 2016 Dec; 14(6):719-727. PubMed ID: 27581117
[TBL] [Abstract][Full Text] [Related]
6. XM17 Follitropin Alfa (Ovaleap(®)): A Review in Reproductive Endocrine Disorders.
Hoy SM
BioDrugs; 2016 Aug; 30(4):379-86. PubMed ID: 27342604
[TBL] [Abstract][Full Text] [Related]
7. Originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilars in Spain: A cost-effectiveness analysis of assisted reproductive technology related to fresh embryo transfers.
Schwarze JE; Venetis C; Iniesta S; Falla E; Lukyanov V; de Agustin Calvo E; D Hooghe T; Roeder C; Matorras R
Best Pract Res Clin Obstet Gynaecol; 2022 Dec; 85(Pt B):203-216. PubMed ID: 35227619
[TBL] [Abstract][Full Text] [Related]
8. A cost-effectiveness evaluation comparing originator follitropin alfa to the biosimilar for the treatment of infertility.
Gizzo S; Garcia-Velasco JA; Heiman F; Ripellino C; Bühler K
Int J Womens Health; 2016; 8():683-689. PubMed ID: 27994486
[TBL] [Abstract][Full Text] [Related]
9. Overlapping biosimilar and originator follitropin alfa preparations: How much closer can they get?
de Mora F; Howles CM
Drug Discov Today; 2022 Aug; 27(8):2071-2075. PubMed ID: 35490965
[TBL] [Abstract][Full Text] [Related]
10. A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany.
Xue W; Lloyd A; Falla E; Roeder C; Papsch R; Bühler K
Int J Womens Health; 2019; 11():319-331. PubMed ID: 31191040
[No Abstract] [Full Text] [Related]
11. An updated meta-analysis comparing the efficacy and safety of biosimilar medicinal products to the original follitropin alfa.
Budani MC; Fensore S; DI Marzio M; Tiboni GM
Minerva Obstet Gynecol; 2024 Feb; 76(1):70-79. PubMed ID: 36534054
[TBL] [Abstract][Full Text] [Related]
12. In-vivo biological activity and glycosylation analysis of a biosimilar recombinant human follicle-stimulating hormone product (Bemfola) compared with its reference medicinal product (GONAL-f).
Mastrangeli R; Satwekar A; Cutillo F; Ciampolillo C; Palinsky W; Longobardi S
PLoS One; 2017; 12(9):e0184139. PubMed ID: 28880909
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.
Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J;
Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of follitropin alpha biosimilars compared to their reference product: a Meta-analysis.
Budani MC; Fensore S; Di Marzio M; Tiboni GM
Gynecol Endocrinol; 2021 May; 37(5):406-414. PubMed ID: 32654532
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars versus the originator of follitropin alfa: Randomized controlled trials are still the best way to evaluate their comparative effectiveness in assisted reproduction.
Venetis CA; Mol BW
Drug Discov Today; 2023 Feb; 28(2):103425. PubMed ID: 36332833
[TBL] [Abstract][Full Text] [Related]
16. The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: a report of the literature.
Šprem Goldštajn M; Mikuš M; Ćorić M; Orešković S; Dumančić S; Noventa M; Buzzaccarini G; Andrisani A; Laganà AS
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):553-558. PubMed ID: 33784935
[No Abstract] [Full Text] [Related]
17. Comparative Assessment of the Structural Features of Originator Recombinant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa Biosimilar Preparations Approved in Non-European Regions.
Manzi L; Sepe N; Migliaccio W; Lanzoni L; Iozzino L; D'Angelo F; Colarusso L; Montenegro S; Palmese A; D'Hooghe T; Ulloa-Aguirre A; Koloda Y; Lispi M
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743204
[TBL] [Abstract][Full Text] [Related]
18. Patient and nurse evaluation of recombinant human follicle-stimulating hormone administration methods: comparison of two follitropin injection pens.
Porter R; Kissel C; Saunders H; Keck C
Curr Med Res Opin; 2008 Mar; 24(3):727-35. PubMed ID: 18230195
[TBL] [Abstract][Full Text] [Related]
19. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled trials do not always fit the purpose: A science-based response to Venetis and Mol's editorial on biosimilars of follitropin alfa.
de Mora F; Howles CM
Drug Discov Today; 2023 May; 28(5):103524. PubMed ID: 36828193
[No Abstract] [Full Text] [Related]
[Next] [New Search]
